Details for Patent: 12,336,995
✉ Email this page to a colleague
Which drugs does patent 12,336,995 protect, and when does it expire?
Patent 12,336,995 protects KRAZATI and is included in one NDA.
This patent has sixteen patent family members in twelve countries.
Summary for Patent: 12,336,995
| Title: | Combination therapies |
| Abstract: | The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor. |
| Inventor(s): | James Gail Christensen, Lars Daniel Engstrom, Ruth Wei Aranda, Jill Hallin, Peter Olson |
| Assignee: | Mirati Therapeutics Inc |
| Application Number: | US17/275,176 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; Device; Dosage form; |
Drugs Protected by US Patent 12,336,995
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | KRAZATI | adagrasib | TABLET;ORAL | 216340-001 | Dec 12, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,336,995
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019340366 | ⤷ Start Trial | |||
| Canada | 3112043 | ⤷ Start Trial | |||
| China | 112955137 | ⤷ Start Trial | |||
| Eurasian Patent Organization | 202190749 | ⤷ Start Trial | |||
| European Patent Office | 3849538 | ⤷ Start Trial | |||
| Israel | 281344 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
